Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Comi, G; Martinelli, V; Rodegher, M; Moiola, L; Leocani, L; Bajenaru, O; Carra, A; Elovaara, I; Fazekas, F; Hartung, HP; Hillert, J; King, J; Komoly, S; Lubetzki, C; Montalban, X; Myhr, KM; Preziosa, P; Ravnborg, M; Rieckmann, P; Rocca, MA; Wynn, D; Young, C; Filippi, M.
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.
Mult Scler. 2013; 19(8):1074-1083
Doi: 10.1177/1352458512469695
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Fazekas Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The placebo-controlled phase of the PreCISe study showed that glatiramer acetate delayed onset of clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome and brain lesions on MRI. To compare the effects of early versus delayed glatiramer acetate treatment in the open-label phase of PreCISe. Patients with a clinically isolated syndrome suggestive of MS with unifocal manifestation and ≥2 T2-weighted brain lesions were randomized to receive glatiramer acetate 20 mg/d (early-treatment, n=198) or placebo (delayed-treatment, n=211) for 36 months or until conversion to CDMS, followed by open-label glatiramer acetate treatment for two years. Early glatiramer acetate treatment reduced CDMS conversion risk by 41% (hazard ratio 0.59, 95% confidence interval 0.44-0.80; p=0.0005) versus delayed-treatment, and was associated with a 972-day delay (185%) in conversion to CDMS, less brain atrophy (-28%, p=0.0209), fewer new T2 lesions/year (-42%, <0.0001) and lower T2 lesion volume (-22%, p=0.0005) versus delayed treatment. Adverse events were consistent with the established safety profile of glatiramer acetate. Effects of early glatiramer acetate treatment on the rate of conversion to CDMS and on MRI measures of disease activity and lesion burden support initiating glatiramer acetate treatment soon after the first clinical symptoms suggestive of MS and continuing treatment to sustain benefits.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Brain - drug effects Brain - pathology
- Demyelinating Diseases - drug therapy Demyelinating Diseases - pathology
- Disease Progression -
- Double-Blind Method -
- Female -
- Humans -
- Immunosuppressive Agents - administration & dosage
- Magnetic Resonance Imaging -
- Male -
- Multiple Sclerosis - prevention & control
- Peptides - administration & dosage
- Find related publications in this database (Keywords)
- Clinically definite multiple sclerosis
- glatiramer acetate
- clinically isolated syndrome (CIS)
- brain atrophy
- MRI
- relapse
- EDSS